Skip to main content
PharmaCorp Rx logo

PharmaCorp Rx — Investor Relations & Filings

Ticker · PCRX TSXV Wholesale and retail trade
Open in API
Filings indexed 115 across all filing types
Latest filing 2026-04-13 Regulatory Filings
Country CA Canada
Listing TSXV PCRX

About PharmaCorp Rx

https://www.pharmacorprx.ca/

PharmaCorp Rx functions as a specialized pharmacy acquisition and ownership platform. Its primary service involves providing comprehensive, personalized succession planning for community pharmacies, facilitating the sale and smooth transition of ownership. The company's model is distinguished by its focus on empowering pharmacists to become equity partners within the acquired entities. PharmaCorp Rx maintains and operates a growing portfolio of retail pharmacies, including those bannered under PharmaChoice, which deliver essential services such as prescription fulfillment and custom compounding specialization.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing the signing of an investor relations services agreement, complete with service terms, fees, and forward-looking statements. It is not a financial report (10-K, IR, ER), not an earnings call transcript, not a dividend notice or capital change, nor a proxy, M&A or board/management change. It is a general regulatory announcement that does not fit a more specific category, so it falls under the Regulatory Filings fallback.
2026-04-13 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a corporate news release announcing an investor relations services agreement with LodeRock Advisors. It does not present financial results or full reports, nor does it fit into more specific categories like capital raising, M&A, dividends, or management changes. It is effectively a general regulatory announcement under TSXV disclosure norms, making "Regulatory Filings (RNS)" the appropriate fallback category.
2026-04-13 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a corporate news release announcing that PharmaCorp has entered into an investor relations services agreement with LodeRock Advisors. It does not present financial results, executive appointments, share transactions, dividends, or regulatory/legal proceedings. It is not a full or interim report, proxy statement, earnings release, or M&A announcement. It is a straightforward disclosure of a material contract and service arrangement and falls into the residual category of general regulatory announcements. Therefore, this is best classified as a Regulatory Filings (RNS).
2026-04-13 English
News release - English.pdf
Share Issue/Capital Change Classification · 1% confidence The document is a press release announcing the grant of stock options to directors, officers, employees, and consultants. This constitutes a change in the company's capital structure and equity compensation. While it involves directors, it is not a 'Director's Dealing' (which refers to personal trades) nor a 'Remuneration Information' report (which is typically a formal disclosure). It fits best under 'Share Issue/Capital Change' as it relates to the issuance of options to purchase common shares.
2026-01-02 English
Material change report - English.pdf
Board/Management Information Classification · 1% confidence The document is a 'Material Change Report' (Form 51-102F3) filed under Canadian securities regulations. It explicitly details an executive transition, including the appointment of a new President/COO and a new Director of Business Development. According to the filing definitions, announcements regarding changes in the company's board of directors or senior management fall under the 'MANG' (Board/Management Information) category.
2025-12-04 English
News release - English.pdf
Earnings Release Classification · 1% confidence The document is a press release titled 'PHARMACORP RX INC. REPORTS Q3 2025 FINANCIAL RESULTS'. It provides a summary of quarterly financial highlights, management commentary, and operational updates. Crucially, it explicitly directs readers to a separate filing on SEDAR+ for the full 'Condensed Consolidated Interim Financial Statements and related Management's Discussion and Analysis'. Because this document is an initial announcement of quarterly results rather than the full financial report itself, it is classified as an Earnings Release. Q3 2025
2025-11-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.